Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Murlentamab - GamaMabs Pharma

Next Previous
Drug Profile

Murlentamab - GamaMabs Pharma

Alternative Names: 3C23K; Anti-AMHR2 monoclonal antibody - GamaMabs; Anti-MISRII humanised monoclonal antibody 3C23K; Anti-mullerian human receptor-II monoclonal antibody - GamaMabs; GM-102; Humanised monoclonal antibody 3C23K

Latest Information Update: 22 Apr 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LFB Biotechnologies
  • Developer GamaMabs Pharma
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Anti-Mullerian hormone receptor antagonists; Antibody-dependent cell cytotoxicity; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer
  • Phase I Gynaecological cancer

Most Recent Events

  • 22 Apr 2022 Murlentamab is still in phase-I development in Gynaecological-cancer (Late-stage disease, Second-line therapy or greater) in France and Belgium (Parenteral) (NCT02978755)
  • 10 Feb 2021 GamaMabs Pharma completes a phase II trial in Colorectal cancer (Second-line therapy or greater, Late-stage disease, Metastatic disease, Combination therapy) in Czech Republic, Belgium (IV) (NCT03799731)
  • 10 Jun 2020 GamaMabs Pharma completes a phase-I trial in Gynaecological cancer (Late-stage disease, Second-line therapy or greater) in United Kingdom, Belgium and France (Parenteral) (NCT02978755)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top